tanzeelbis's blog

According to a survey conducted in 2021 in the U.S., the top unmet needs cited by patients and healthcare professionals (HCPs) include the requirement for non-scheduled therapeutic options or no/low abuse drug potential, more tolerable drug regime, a more effective and novel mechanism of action beyond presently available therapies, and reduced dose medications. In addition, the disorder profoundly increases the psychosocial burden on people with narcolepsy.

Cancer is one of the leading causes of death worldwide, with millions of new cases diagnosed each year. Traditional methods of cancer diagnosis involve invasive procedures like biopsies, which can be painful and carry risks of complications. However, there is now a new type of diagnostic test called liquid biopsy that offers a non-invasive and more convenient way of detecting cancer. In this blog, we'll take a closer look at liquid biopsy and how it works.

What is Liquid Biopsy?

Microbiome therapeutic products, with their novel composition as well as the mechanism of action, provide a safer alternative. Several indications such as C. diff. Infection, where recurrence of the disease is a major issue; microbiome therapeutics have demonstrated promising results in clinical studies and appear to become a treatment of choice. Additionally, researchers have been putting significant efforts into establishing the role of microbiome therapeutics in treating other indications as well. Indications such as skin disorders and oncology have drawn a lot of attention.

The global increase in the cancer burden has significantly increased the need for flow cytometry-based products to conduct screening and therapeutic monitoring during cancer treatment. Flow cytometry is one of the well established screening methods in the field of oncology and immunology, which enables healthcare professionals to define cell types in a heterogeneous cell population through the analysis of underlying cellular expressions. Primary immunodeficiencies (PIDs) are a diverse set of immune system hereditary disorders.

The successes of cell and gene-based treatments have spurred endeavors to introduce such therapies into the market. As the need arises to cater to the clinical and commercial production of cells, coupled with the growing amount of extensive clinical data stemming from these therapies, a greater emphasis on the biomanufacturing requirement has become crucial. The high demand for the therapies is driving the growth of cell and gene therapy biomanufacturers and creating ample opportunities for them to expand in various geographies and strengthen their market presence.

The healthcare system is adopting advanced technologies, especially in the field of surgical medicine, to improve surgical workflow patterns and develop in-depth and accurate clinical outcomes. The use of a surgical robotic system offers a safer surgical procedure by making it more accurate and minimally invasive for patients. Advanced technologies such as surgical robotics have been developed to offer more precise and optimum surgical outcomes. Despite the availability of various techniques, the pull of technology into the marketplace is still fragmented and incomplete.

Serum-Free Media Market was valued at $1,022.4 million in 2021 and is expected to reach $3,920.5 million by 2032, registering a CAGR of 12.73% during the forecast period 2022-2032. The growth in the global serum-free media market is expected to be driven by factors such as the low risk of contamination in the media, rising awareness of media-based diagnostic testing, and significant funding for executing research and development.
Market Lifecycle Stage

In 2021, the NGS Kits Market was valued at $4,553.6 million, and it is expected to reach $26,057.4 million by 2032, growing at a CAGR of 17.27% during the forecast period 2022-2032. The growth in the global NGS Kits market is expected to be driven by advancements in sequencing technology benefiting the treatment and diagnostics coupled with the presence of regulatory framework pertaining to sequencing and governments investing in large clinical and diagnostic laboratories to enable reliable NGS testing for a variety of chronic and infectious ailments.
Market Lifecycle Stage

Laboratory informatics plays an essential role in laboratories fulfilling quality standards, eliminating transcribing mistakes, shortening the time it takes from specimen receipt to results reporting, and improving patient outcomes. Over the last decade, technical developments in laboratory equipment have resulted in increasing specimen numbers, as well as a growing need for and dependence on laboratory data to support clinical and public health demands.

While radiation exposure from medical imaging has witnessed a declining trend in the past few years owing to technological advancements such as the incorporation of dose-lowering technologies in imaging systems, the concern regarding the harmful and biological effects of radiation exposure is still prevalent.